Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Receives Complete Response, Warning Letters For Lumizyme

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite receiving a “complete response” letter and manufacturing warning letter on the same day, Genzyme remains upbeat about the likelihood of approval for its 2,000L scale-up of Myozyme.

You may also be interested in...



Good News For A Change At Genzyme: Consent Decree Finalized Without Surprises, Lumizyme Approved By FDA Ahead Of Schedule

Belying the adage that no news is good news, embattled Genzyme enjoyed two measures of positive news in the past week. But activist investors continue circling the company, which is not yet out of the deep water

Good News For A Change At Genzyme: Consent Decree Finalized Without Surprises, Lumizyme Approved By FDA Ahead Of Schedule

Belying the adage that no news is good news, embattled Genzyme enjoyed two measures of positive news in the past week. But activist investors continue circling the company, which is not yet out of the deep water

FDA Immunogenicity Testing Guidance Is High-Wire Act For Brand Industry

The biotech industry faces a tightrope challenge in commenting on FDA's draft guidance on assay development for immunogenicity testing of therapeutic proteins. Companies want clarity from the agency, as well as limits to the scope of the guidelines. But firms also want to make sure that however the lines are drawn, follow-on biologics have strict testing requirements

Related Content

Topics

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel